Our goal is clear – to be the leading platform for niche established medicines with advanced commercial capabilities in Western Europe.
We will do this by investing significantly in our portfolio through a combination of pipeline development and acquisition.
We will broaden our geographic strength, enhance our niche product focus and build a natural emphasis on specialist channels and capabilities.
What do we mean by ‘advanced commercial capability’?
Over the next few years, we will focus on growing our portfolio to provide greater choice for payors, prescribers and patients and a robust supply so that patients can continue to benefit from these medicines.
We will do this in three ways:
By developing medicines currently in our pipeline through a combination of revitalisation and innovation.
By acquiring niche established medicines from across the globe that fit well with our portfolio and extensive global commercial capabilities in over 90 markets.
By expanding our commercial capabilities in Western Europe through acquiring companies with established infrastructures in markets such as Germany, Italy, Spain and France.